Dianthus Therapeutics, Inc. /DE/ Expense Breakdown
No Expense Breakdown for DNTH on this site yet.
- 2026-06-30: Personnel and Related Costs $9.25M; Share Based Compensation Expense $5.64M; Discovery Expenses $2.31M; Other Costs $1.98M.
- 2025-06-30: Personnel and Related Costs $5.96M; Share Based Compensation Expense $2.46M; Discovery Expenses $168.00K; Other Costs $1.21M.
Source checked: the stored Expense Breakdown page for DNTH.
Expenses by product
Research and development: each quarter (3 month)
| Quarter end | Personnel and Related Costs | Share Based Compensation Expense | Discovery Expenses | Other Costs |
|---|
| 2026-06-30 | $9.25M | $5.64M | $2.31M | $1.98M |
|---|
| 2025-06-30 | $5.96M | $2.46M | $168.00K | $1.21M |
|---|
General and Administrative Expense: each quarter (3 month)
| Quarter end | Personnel and Related Costs | Share Based Compensation Expense | Other Costs |
|---|
| 2026-06-30 | $4.13M | $6.25M | $3.17M |
|---|
| 2025-06-30 | $2.79M | $3.25M | $2.83M |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
|---|
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
|---|
| Veradermics, Inc (MANE) | United States | $4.839B | |
|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
|---|
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
|---|
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
|---|